NCT02006160View on ClinicalTrials.gov

Effects of Dalfampridine on Cognition in Multiple Sclerosis

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

February 29, 2016

Study Completion Date

February 29, 2016

Conditions
Multiple Sclerosis
Interventions
DRUG

dalfampridine

10 mg bid

DRUG

placebo

10 mg bid

Trial Locations (1)

14203

Buffalo General Hospital, Buffalo

All Listed Sponsors
lead

State University of New York at Buffalo

OTHER

NCT02006160 - Effects of Dalfampridine on Cognition in Multiple Sclerosis | Biotech Hunter | Biotech Hunter